Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2012

01-02-2012 | Preclinical Study

Loss of Yes-associated protein (YAP) expression is associated with estrogen and progesterone receptors negativity in invasive breast carcinomas

Authors: Rozina Tufail, Mercy Jorda, Wei Zhao, Isildinha Reis, Zafar Nawaz

Published in: Breast Cancer Research and Treatment | Issue 3/2012

Login to get access

Abstract

Yes-associated protein (YAP) is a well characterized transcriptional coactivator that interacts with various transcription factors and modulates their transcriptional activities. Phosphorylation of YAP by specific kinases regulates its cellular distribution and transcriptional activation functions. Sequestration of phosphorylated YAP in cytoplasm results in the reduction of transcription from its target genes. Since, YAP has been characterized as a coactivator of estrogen (ER) and progesterone (PR) receptors, we examined the immunohistochemical expression profile of YAP and correlation of YAP expression with that of ER and PR in normal (40 samples) and tumor breast (226 samples) from microarray tissue samples using immunohistochemistry. Here we show that YAP expression is significantly reduced in invasive carcinoma samples compared to normal breast tissues, which express high levels of YAP (YAP was positive for 45.1% of invasive carcinoma samples versus 82.5% of normal samples P < 0.0001). Furthermore, the data shows that reduced expression of YAP in invasive carcinoma samples is significantly associated with ER negativity (YAP was negative for 59.9% in ER negative versus 38.9% in ER positive invasive carcinoma samples, P = 0.007) and PR negativity (YAP was negative for 60.1% in PR negative versus 28.9% in PR positive, P = 0.0004). Among invasive carcinoma samples, 42.9% were YAP, ER, and PR negative, whereas only 7.5% were found to be YAP, ER, and PR positive. On the contrary, 20 out of 23 (87%) normal breast tissues that were positive for ER and PR were also positive for YAP. These data suggest that YAP may act as a tumor suppressor in invasive breast carcinomas and it can also be used as a molecular marker for ER and PR negative breast tumors.
Literature
1.
go back to reference Sudol M (1994) Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. Oncogene 9:2145–2152PubMed Sudol M (1994) Yes-associated protein (YAP65) is a proline-rich phosphoprotein that binds to the SH3 domain of the Yes proto-oncogene product. Oncogene 9:2145–2152PubMed
2.
go back to reference Sudol M, Recinos CC, Abraczinskas J, Humbert J, Farooq A (2005) WW or WoW: the WW domains in a union of bliss. IUBMB Life 57:773–778PubMedCrossRef Sudol M, Recinos CC, Abraczinskas J, Humbert J, Farooq A (2005) WW or WoW: the WW domains in a union of bliss. IUBMB Life 57:773–778PubMedCrossRef
3.
4.
go back to reference Yagi R, Chen LF, Shigesada K, Murakami Y, Ito Y (1999) A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator. EMBO J 18:2551–2562PubMedCrossRef Yagi R, Chen LF, Shigesada K, Murakami Y, Ito Y (1999) A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator. EMBO J 18:2551–2562PubMedCrossRef
6.
go back to reference Basu S, Totty NF, Irwin MS, Sudol M, Downward J (2003) Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14–3-3 and attenuation of p73-mediated apoptosis. Mol Cell 11:11–23PubMedCrossRef Basu S, Totty NF, Irwin MS, Sudol M, Downward J (2003) Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14–3-3 and attenuation of p73-mediated apoptosis. Mol Cell 11:11–23PubMedCrossRef
7.
go back to reference Overholtzer M, Zhang J, Smolen GA et al (2006) Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci USA 103:12405–12410PubMedCrossRef Overholtzer M, Zhang J, Smolen GA et al (2006) Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci USA 103:12405–12410PubMedCrossRef
8.
go back to reference Steinhardt AA, Gayyed MF, Klein AP et al (2008) Expression of Yes-associated protein in common solid tumors. Hum Pathol 39:1582–1589PubMedCrossRef Steinhardt AA, Gayyed MF, Klein AP et al (2008) Expression of Yes-associated protein in common solid tumors. Hum Pathol 39:1582–1589PubMedCrossRef
9.
go back to reference Strano S, Munarriz E, Rossi M et al (2001) Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J Biol Chem 276:15164–15173PubMedCrossRef Strano S, Munarriz E, Rossi M et al (2001) Physical interaction with Yes-associated protein enhances p73 transcriptional activity. J Biol Chem 276:15164–15173PubMedCrossRef
10.
go back to reference Zhao B, Ye X, Yu JD et al (2008) TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 22:1962–1971PubMedCrossRef Zhao B, Ye X, Yu JD et al (2008) TEAD mediates YAP-dependent gene induction and growth control. Genes Dev 22:1962–1971PubMedCrossRef
11.
go back to reference Ehsanian R, Brown M, Lu H et al (2010) YAP dysregulation by phosphorylation or DeltaNp63-mediated gene repression promotes proliferation, survival and migration in head and neck cancer subsets. Oncogene 29:6160–6171PubMedCrossRef Ehsanian R, Brown M, Lu H et al (2010) YAP dysregulation by phosphorylation or DeltaNp63-mediated gene repression promotes proliferation, survival and migration in head and neck cancer subsets. Oncogene 29:6160–6171PubMedCrossRef
12.
go back to reference Yuan M, Tomlinson V, Lara R et al (2008) Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death Differ 15:1752–1759PubMedCrossRef Yuan M, Tomlinson V, Lara R et al (2008) Yes-associated protein (YAP) functions as a tumor suppressor in breast. Cell Death Differ 15:1752–1759PubMedCrossRef
13.
go back to reference Allred DC, Wu Y, Mao S et al (2008) Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res 14:370–378PubMedCrossRef Allred DC, Wu Y, Mao S et al (2008) Ductal carcinoma in situ and the emergence of diversity during breast cancer evolution. Clin Cancer Res 14:370–378PubMedCrossRef
15.
go back to reference Horwitz K, Clarke C (1998) Estrogens and progestins in mammary development and neoplasia. Introduction. J Mammary Gland Biol Neoplasia 3:1–2PubMedCrossRef Horwitz K, Clarke C (1998) Estrogens and progestins in mammary development and neoplasia. Introduction. J Mammary Gland Biol Neoplasia 3:1–2PubMedCrossRef
16.
go back to reference Naccarato AG, Viacava P, Vignati S et al (2000) Bio-morphological events in the development of the human female mammary gland from fetal age to puberty. Virchows Arch 436:431–438PubMedCrossRef Naccarato AG, Viacava P, Vignati S et al (2000) Bio-morphological events in the development of the human female mammary gland from fetal age to puberty. Virchows Arch 436:431–438PubMedCrossRef
17.
go back to reference Bryan BB, Schnitt SJ, Collins LC (2006) Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol 19:617–621PubMedCrossRef Bryan BB, Schnitt SJ, Collins LC (2006) Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer. Mod Pathol 19:617–621PubMedCrossRef
18.
go back to reference Benz CC, Scott GK, Sarup JC et al (1992) Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24:85–95PubMedCrossRef Benz CC, Scott GK, Sarup JC et al (1992) Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat 24:85–95PubMedCrossRef
19.
go back to reference Clark GM, McGuire WL (1988) Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 15:20–25PubMed Clark GM, McGuire WL (1988) Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 15:20–25PubMed
20.
go back to reference Clarke RB, Anderson E, Howell A (2004) Steroid receptors in human breast cancer. Trends Endocrinol Metab 15:316–323PubMedCrossRef Clarke RB, Anderson E, Howell A (2004) Steroid receptors in human breast cancer. Trends Endocrinol Metab 15:316–323PubMedCrossRef
21.
go back to reference Putti TC, El-Rehim DM, Rakha EA et al (2005) Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol 18:26–35PubMedCrossRef Putti TC, El-Rehim DM, Rakha EA et al (2005) Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol 18:26–35PubMedCrossRef
22.
go back to reference Dhananjayan SC, Ramamoorthy S, Khan OY et al (2006) WW domain binding protein-2, an E6-associated protein interacting protein, acts as a coactivator of estrogen and progesterone receptors. Mol Endocrinol 20:2343–2354PubMedCrossRef Dhananjayan SC, Ramamoorthy S, Khan OY et al (2006) WW domain binding protein-2, an E6-associated protein interacting protein, acts as a coactivator of estrogen and progesterone receptors. Mol Endocrinol 20:2343–2354PubMedCrossRef
23.
go back to reference Zhao B, Wei X, Li W et al (2007) Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 21:2747–2761PubMedCrossRef Zhao B, Wei X, Li W et al (2007) Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev 21:2747–2761PubMedCrossRef
24.
go back to reference Kastner P, Krust A, Turcotte B et al (1990) Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 9:1603–1614PubMed Kastner P, Krust A, Turcotte B et al (1990) Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 9:1603–1614PubMed
25.
go back to reference Khan OY, Fu G, Ismail A et al (2006) Multifunction steroid receptor coactivator, E6-associated protein, is involved in development of the prostate gland. Mol Endocrinol 20:544–559PubMedCrossRef Khan OY, Fu G, Ismail A et al (2006) Multifunction steroid receptor coactivator, E6-associated protein, is involved in development of the prostate gland. Mol Endocrinol 20:544–559PubMedCrossRef
26.
go back to reference McKenna NJ, Xu J, Nawaz Z, Tsai SY, Tsai MJ, O’Malley BW (1999) Nuclear receptor coactivators: multiple enzymes, multiple complexes, multiple functions. J Steroid Biochem Mol Biol 69:3–12PubMedCrossRef McKenna NJ, Xu J, Nawaz Z, Tsai SY, Tsai MJ, O’Malley BW (1999) Nuclear receptor coactivators: multiple enzymes, multiple complexes, multiple functions. J Steroid Biochem Mol Biol 69:3–12PubMedCrossRef
27.
go back to reference Bertini E, Oka T, Sudol M, Strano S, Blandino G (2009) YAP: at the crossroad between transformation and tumor suppression. Cell Cycle 8:49–57PubMedCrossRef Bertini E, Oka T, Sudol M, Strano S, Blandino G (2009) YAP: at the crossroad between transformation and tumor suppression. Cell Cycle 8:49–57PubMedCrossRef
Metadata
Title
Loss of Yes-associated protein (YAP) expression is associated with estrogen and progesterone receptors negativity in invasive breast carcinomas
Authors
Rozina Tufail
Mercy Jorda
Wei Zhao
Isildinha Reis
Zafar Nawaz
Publication date
01-02-2012
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2012
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-011-1435-0

Other articles of this Issue 3/2012

Breast Cancer Research and Treatment 3/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine